The Zhitong Finance App learned that Cansino Biotech (06185) is now up more than 4%, with a cumulative increase of more than 18% during the month. As of press release, it rose 4.1% to HK$18.8, with a turnover of HK$17.022,600.

According to the news, Cansino Biotech recently announced that the freeze-dried Haemophilus influenzae type b (Hib vaccine) conjugate vaccine (Hib vaccine) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials. Haemophilus influenzae is a gram-negative bacillus and is one of the most important pathogens of acute lower respiratory infections in children.

Cansino Biotech also announced earlier that the recombinant pneumococcal protein vaccine (PBPV) developed by the company obtained positive initial results in phase I clinical trials. The results showed that PBPV had good safety in adults and the elderly, and no grade 3 adverse effects or special safety risks were observed. The company will evaluate and plan the next stage of PBPV research and development based on the preliminary results obtained in the phase I clinical trial.

CITIC Construction Investment said earlier that in 2023, Cansino Biotech's profit side was affected by factors such as a sharp drop in COVID-19 vaccine revenue, reduction in returns, and asset impairment. The apparent loss increased. It is expected that this part of the impact will be drastically reduced in 24. Combined with revenue growth and cost scale control, the overall loss is expected to narrow drastically. The bank pointed out that MCV series products are the company's main products. As local promotion and entry results are achieved, channel construction is being completed, and the products are expected to usher in further volume, driving the company's non-COVID-19 vaccine revenue to grow rapidly.